Th1Th17 CM lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author Quirant-Sánchez, Bibiana
  • dc.contributor.author Presas-Rodriguez, Silvia
  • dc.contributor.author Mansilla, María José
  • dc.contributor.author Teniente-Serra, Aina
  • dc.contributor.author Hervás-García, José V.
  • dc.contributor.author Brieva, Luis
  • dc.contributor.author Moral-Torres, Ester
  • dc.contributor.author Cano, Antonio
  • dc.contributor.author Munteis Olivas, Elvira
  • dc.contributor.author Navarro-Barriuso, Juan
  • dc.contributor.author Martínez-Cáceres, Eva M.
  • dc.contributor.author Ramo-Tello, Cristina
  • dc.date.accessioned 2020-03-03T08:27:09Z
  • dc.date.available 2020-03-03T08:27:09Z
  • dc.date.issued 2019
  • dc.description.abstract Peripheral blood biomarkers able to predict disease activity in multiple sclerosis (MS) patients have not been identified yet. Here, we analyzed the immune phenotype of T lymphocyte subpopulations in peripheral blood samples from 66 RRMS patients under DMF (n = 22) or fingolimod (n = 44) treatment, by flow cytometry. A correlation study between the percentage and absolute cell number of each lymphocyte subpopulation with the presence of relapses or new MRI lesions during 12-month follow-up was performed. Patients who had undergone relapses showed at baseline higher percentage of Th1CM cells (relapsed: 11.60 ± 4.17%vs. nonrelapsed: 9.25 ± 3.17%, p < 0.05) and Th1Th17CM cells (relapsed: 15.65 ± 6.15%vs. nonrelapsed: 10.14 ± 4.05%, p < 0.01) before initiating DMF or fingolimod treatment. Kaplan-Meier analysis revealed that patients with Th1Th17CM (CD4+CCR7+CD45RA-CCR6+CXCR3+) cells > 11.48% had a 50% relapse-free survival compared to patients with Th1Th17CMcells < 11.48% whose relapse-free survival was 88% (p = 0.013, log-rank test). Additionally, a high percentage of Th1Th17CM cells was also found in patients with MRI activity (MRI activity: 14.02 ± 5.87%vs. no MRI activity: 9.82 ± 4.06%, p < 0.01). Our results suggest that the percentage of Th1Th17CM lymphocytes at baseline is a predictive biomarker of activity during the first 12 months of treatment, regardless of the treatment.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation Quirant-Sánchez B, Presas-Rodriguez S, Mansilla MJ, Teniente-Serra A, Hervás-García JV, Brieva L. et al. Th1Th17 CM lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment. Mediators Inflamm. 2019 Jun 26; 2019 :8147803. DOI: 10.1155/2019/8147803
  • dc.identifier.doi http://dx.doi.org/10.1155/2019/8147803
  • dc.identifier.issn 0962-9351
  • dc.identifier.uri http://hdl.handle.net/10230/43762
  • dc.language.iso eng
  • dc.publisher Hindawi
  • dc.rights Copyright © 2019 Bibiana Quirant-Sánchez et al. This is an open access article distributed under the Creative Commons Attribution License, https://creativecommons.org/licenses/by/4.0/ which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri https://creativecommons.org/licenses/by/4.0/
  • dc.subject.other Esclerosi múltiple -- Tractament
  • dc.title Th1Th17 CM lymphocyte subpopulation as a predictive biomarker of disease activity in multiple sclerosis patients under dimethyl fumarate or fingolimod treatment
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion

Col·leccions

Articles (Hospital del Mar Research Institute)